Woodmont Investment Counsel LLC Sells 75 Shares of Zoetis Inc. (NYSE:ZTS)

Woodmont Investment Counsel LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,484 shares of the company’s stock after selling 75 shares during the period. Woodmont Investment Counsel LLC’s holdings in Zoetis were worth $290,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Envestnet Portfolio Solutions Inc. raised its stake in shares of Zoetis by 14.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 67,411 shares of the company’s stock worth $11,407,000 after acquiring an additional 8,427 shares during the last quarter. Empowered Funds LLC raised its position in Zoetis by 26.3% in the 1st quarter. Empowered Funds LLC now owns 8,017 shares of the company’s stock worth $1,357,000 after purchasing an additional 1,671 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its holdings in Zoetis by 13.1% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 1,980 shares of the company’s stock worth $335,000 after buying an additional 230 shares in the last quarter. Lipe & Dalton boosted its position in Zoetis by 23.4% in the 1st quarter. Lipe & Dalton now owns 5,542 shares of the company’s stock valued at $938,000 after buying an additional 1,051 shares during the last quarter. Finally, Highland Capital Management LLC increased its stake in shares of Zoetis by 0.8% in the 1st quarter. Highland Capital Management LLC now owns 39,883 shares of the company’s stock valued at $6,749,000 after buying an additional 312 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 2.3 %

Shares of NYSE ZTS opened at $174.34 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The stock has a market cap of $78.65 billion, a price-to-earnings ratio of 32.77, a P/E/G ratio of 2.61 and a beta of 0.90. The company has a quick ratio of 2.09, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company’s fifty day moving average is $188.46 and its 200-day moving average is $179.17.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities research analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. Zoetis’s payout ratio is 32.52%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ZTS shares. BTIG Research upped their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.